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OPEN
ORIGINAL ARTICLE
Associations between the schizophrenia susceptibility gene
ZNF804A and clinical outcomes in psychosis
A Wickramasinghe1,3, AD Tulloch1,3, RD Hayes1, C-K Chang1, M Broadbent2, M Di Forti1, RM Murray1, C Iyegbe1,4 and R Stewart1,4
We sought to test the hypothesis that the rs1344706 A allele will be associated with worse clinical outcome in ﬁrst-episode
psychosis. A data linkage was set up between a large systematic study of ﬁrst-episode psychosis and an electronic health-record
case register at the South London and Maudsley NHS Foundation Trust—a large provider of secondary mental-health care. A
sample of 291 patients, who presented with a ﬁrst psychotic episode (ICD10 diagnoses F20–29 or F30–33) and in whom the
rs1344706 genotype had been assayed, were followed to examine the duration of mental-health in-patient care during the 2 years
following ﬁrst service contact, as a primary outcome. Secondary outcome measures were whether or not an in-patient episode
occurred and the number of in-patient episodes during this period. A strong association was found between the number of
rs1344706 A alleles and the cumulative duration of mental-health in-patient stay over the 2 years since initial presentation. In the
84.2% who experienced an in-patient episode during this period, the mean duration of admission was an additional 38 days for
each A allele increment. Therefore, in addition to its potential role as a risk factor for psychosis, the ZNF804A rs1344706 A allele is
associated with worse clinical outcome.
Translational Psychiatry (2015) 5, e698; doi:10.1038/tp.2015.198; published online 15 December 2015
INTRODUCTION
Outcomes of psychotic disorder show substantial between-
individual variation,1,2 and genetic factors have been suggested
to have a part in this.3,4 Recent genome-wide association studies
have suggested that the risk of psychosis may be conveyed by
multiple genes of small effect, and that the ensemble of variants
involved may be different for each individual.5 Although it is still
uncertain whether these genetic variants deﬁne subgroups within
psychosis,6 or symptoms that might be shared across multiple
disorders,7 it remains likely that an individual’s genetic composi-
tion will also predict certain psychosis characteristics and
outcomes.8
The single-nucleotide polymorphism (SNP) rs1344706 (A/C) at
the second intron of gene ZNF804A (OMIM612282) on 2q32.1 is
the most widely supported of all the genome-wide association
studies-identiﬁed risk factors in schizophrenia.9 However, the A
allele of rs1344706, the risk variant in this gene, has consistently
shown stronger associations when replicated for patient samples
combining schizophrenia and bipolar disorder.10,11 Although it is
known that the ZNF804A gene encodes a zinc-ﬁnger family
protein called ZNF804A, its function remains poorly characterised.
Despite putative associations with the risk of psychotic disorder,
there has been little research to date on associations between
ZNF804A and clinical outcomes. Capitalising on a data linkage
between a large genetic database and an electronic mental-health
record, we investigated the association between the ZNF804A
genotype and two measures of early clinical outcomes: duration of
in-patient admission and number of in-patient episodes. We
hypothesised that the A allele, proposed to be associated with
increased risk of developing psychosis, would also be associated




The sample analysed comprised patients with ﬁrst-episode psychosis
from the Genetics and Psychosis (GAP) study.12–14 All cases were recruited
between 2004 and 2010 at their ﬁrst presentation to the South
London and Maudsley NHS Foundation Trust: a large, near-monopoly
provider of mental-health care to a geographic catchment of ~ 1.2 million
residents in southeast London. All GAP participants were aged between
18 and 65 years, and met ICD10 diagnostic criteria for functional
psychosis (F20–29 or F30–33). Diagnoses were validated using the
Schedules for Clinical Assessment in Neuropsychiatry (WHO 1992)
administered by trained researchers. Ethical approval for the GAP study
was granted by the South London and Maudsley and Institute of Psychiatry
Research Ethics Committee, and all participants provided informed written
consent.
Data linkage
GAP study participant data were linked to the Clinical Record Interactive
Search (CRIS) application that derives full but de-identiﬁed data from the
electronic patient records used by South London and Maudsley NHS
Foundation Trust. CRIS has been described in detail,15 and currently
accesses over 250 000 mental-health records. All GAP participants had
provided prior consent for medical records' access. Identiﬁer ﬁelds from
291 incident cases of ﬁrst-episode psychosis were thus successfully linked
with the clinical records' database.
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Genotyping
DNA for these 291 patients had previously been extracted from either a
blood sample or a cheek swab, using a standard phenol–chloroform
method. Genotype status at the rs1344706 locus within ZNF804A was
ascertained using an off-the-shelf Taqman SNP genotyping kit (http//www.
appliedbiosystems.com; C_2834835_10). Reactions were run on a 7900HT
sequence detection system (Applied Biosystems, Foster City, CA, USA). All
the 291 cases used in the study yielded an unambiguous genotyping result
(100% call rate). The distribution of genotypes at rs1344706 were within
Hardy–Weinberg equilibrium (P40.05) for the 291 cases.14
Genetic ancestry was derived using a panel of 57 ancestry informative
genetic markers. These were genotyped using the iPLEX technology
developed for MassArray platform (Sequenom, San Diego, CA, USA).
Further information on the makeup of the marker panel is available on
request. Ancestry scores were derived using the programme STRUCTURE
to implement a model-based (Markov Chain Monte Carlo) clustering
algorithm. Having determined the best solution for K (the probable true
number of underlying genetic groups in the GAP study sample), a three-
way ancestral axis for black African, white Caucasian and Asian ancestry
was created, using an ancestry score of ⩾ 98% as the membership criterion
for the reference group. Genetic ancestry was used as a covariate in the
regression model as differences in rs1344706 allele frequencies have been
observed between populations (http://www.ncbi.nlm.nih.gov/projects/
SNP/snp_ref.cgi?rs = 1344706).
Assessment of outcomes
A follow-up period of 2 years was deﬁned for each GAP participant from
their ﬁrst mental-health services contact with psychotic illness. Date of ﬁrst
contact with mental-health services was extracted from CRIS. The primary
outcome, deﬁned a priori, was the time spent in mental-health in-patient
care during the ﬁrst 2 years. This, and a secondary outcome measure of
number of in-patient episodes for the same period were derived from CRIS.
Any outcome data recorded before 1 April 2006 were manually cross-
checked because of less comprehensive structure in the electronic patient
records before that date.
Covariates
The following additional data were extracted and used in analyses: age at
presentation, gender and marital status (categorised into married/
cohabiting or other). Information on the ﬁrst functional psychosis diagnosis
recorded in the health record was also obtained from CRIS and classiﬁed
into schizophreniform (ICD10 F20–29 codes) or non-schizophreniform
illnesses. Further exploratory analyses made use of structured data from
the Health of the Nation Outcomes Scales (HoNOS),16 which are routinely
completed by keyworkers in UK mental-health services for administrative
returns. Speciﬁcally, where recorded, the highest scores during the 2-year
surveillance period were derived on the following HoNOS scales: (i)
agitated behaviour, (ii) cognitive impairment, (iii) hallucinations and
delusions, (iv) depressed mood and (v) problems with activities of daily
living. Subscales are rated by clinicians on a 0–4 ordinal scale indicating no
problems (0), minor problems requiring no action (1), mild problems but
deﬁnitely present (2), moderately severe problem (3) and severe to very
severe problem (4). For the purpose of these analyses, HoNOS subscale
scores were condensed to categorise the deﬁned features as present
(score 2–4) or absent (0–1).
Statistical analysis
Data were extracted using SQL, and analyses were performed using Stata
12 (StataCorp, College Station, TX, USA). The distributions of socio-
demographic and diagnostic variables by genotype were described in a
series of bivariate analyses. Initial analyses compared the duration of in-
patient care calculated for the 2-year surveillance period between
rs1344706 genotypes AA, AC and CC. Genotypes were then coded to
reﬂect rs1344706 A allele dosage. Linear regression models with boot-
strapping were ﬁtted to analyse duration of in-patient care, entering
sociodemographic and diagnostic covariates separately and in combina-
tion to assess the impact of these adjustments on the association of
interest. A post hoc power calculation for a linear regression analysis (based
on duration of in-patient admission) indicated that a small-to-medium
effect size (f2 = 0.035) could be detected at 90% power (alpha 0.05) with
the linked sample of the 291 cases.
RESULTS
As displayed in Table 1, among the study sample of 291 patients
with ﬁrst-episode psychosis, no differences were observed in age,
gender or diagnosis by rs1344706 genotypes. The A allele was
positively associated with single status, with higher mean black
African ancestry score and with lower white Caucasian and Asian
ancestry scores.
Of the 291 cases, 245 (84.2%) experienced at least 1 day’s in-
patient care between initial presentation and the end of the
follow-up period (Table 2). These proportions did not differ
signiﬁcantly between genotypes (Χ2= 0.27 (1 degree of freedom),
P= 0.60; Fisher’s Exact Test P= 0.90), and the median number of
admissions was one in all three genotypes. However, the mean
total duration of in-patient admission was higher with increasing A
allele dose. This was conﬁrmed in linear regression models with
bootstrapping, whether the sample was analysed as a whole or
restricted to those with at least one in-patient admission, and little
altered in strength following adjustments (Table 3). Among those
who experienced at least one in-patient admission, the fully
adjusted coefﬁcients indicated an increased total duration of in-
patient admission of 38 days for each A allele increment.
In further exploratory analyses of characteristics derived from
HoNOS scores recorded during the 2-year observation period, no
signiﬁcant group differences were observed between genotypes
(Table 4), and no meaningful differences were observed in either
the strength or statistical signiﬁcance of associations between
genotype and duration of in-patient stay following adjustment for
these characteristics.
Table 1. Sample characteristics by the rs1344706 genotype
Variables AA (N= 178) AC (N= 93) CC (N= 20) Total (N= 291) P-valuea
Mean (s.d.) age, years 27.6 (7.9) 28.1 (8.9) 30.6 (7.6) 27.9 (8.2) 0.59
Mean (s.d.) black African genetic ancestry score 0.630 (0.395) 0.196 (0.297) 0.106 (0.191) 0.456 (0.418) o0.001
Mean (s.d.) white Caucasian genetic ancestry score 0.244 (0.328) 0.491 (0.361) 0.580 (0.361) 0.346 (0.364) o0.001
Mean (s.d.) Asian genetic ancestry score 0.124 (0.210) 0.314 (0.327) 0.314 (0.328) 0.198 (0.277) o0.001
AA AC CC Total P-valueb Χ2 (df)
Male gender (n, %) 122 (68.5) 55 (59.1) 11 (55.0) 188 (64.6) 0.08 3.09 (1)
Single relationship status (n, %) 160 (89.9) 80 (86.0) 14 (70.0) 254 (87.3) 0.02 5.24 (1)
Schizophreniform diagnosis (n, %) 111 (66.9) 53 (60.9) 09 (47.4) 173 (63.6) 0.09 2.95 (1)
Abbreviation: df, degree of freedom. aLinear regression (modelling the covariate against number of A alleles) . bΧ2-test applied to the cross-tabulation between
the covariate and genotype.
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DISCUSSION
Using linked genetic and clinical data on a sample with ﬁrst-
episode psychosis, we found evidence for a strong association
between the ZNF804A rs1344706 A allele and longer cumulative
duration of in-patient admissions during the 2 years following ﬁrst
clinical presentation. Although this SNP has been implicated as a
risk factor for developing psychotic illness, to our knowledge, ours
is the ﬁrst demonstration of a relationship with subsequent clinical
outcome.
The analyses presented here were planned and carried out a
priori, and at the time of manuscript submission, ZNF804A
rs1344706 was the only SNP to have been evaluated against
these clinical outcomes in this cohort. This study sought to
determine whether the newly emerged common genetic archi-
tecture of schizophrenia has potential clinical value beyond simply
conveying liability to illness. Given that genome-wide association
study data were not available for the majority of this cohort, the
choice of an a priori candidate was central to the hypothesis. The
most objective way to select the candidate in this case was a
principled approach, where the most representative common
genetic risk factor for schizophrenia was sought. The most
replicated genome-wide association study signal for schizophrenia
is attributable to the rs1344706 locus in ZNF804A, and this was
therefore the archetypal common risk factor for psychosis (that is,
schizophrenia and bipolar disorder). In addition, with the
exception of ancestry informative markers (n~ 55; see Materials
and methods), genetic characterisation of the GAP cohort was
extremely limited at the time of analysis.
The plausibility of the ﬁnding and potential causal pathways
require consideration. With regards to functionality, rs1344706
maps to the noncoding genome (that is, intron 2 of ZNF804A) and
thus is likely to have regulatory effects on gene expression17
rather than consequences for protein structure.18 The gene
demonstrates a temporally sensitive pattern of expression over
the human lifespan, with maximum expression levels in utero.19,20
Association of the rs1344706 risk locus with allelic expression has
been reported, possibly speciﬁc to in utero development,20,21 and
is potentially attributable to splicing.20 However, it remains
unclear whether the relationship between rs1344706 and
expressed ZNF804A levels is sustained into adulthood. Allelic
variation at rs1344706 reﬂects varying afﬁnity of the gene for
nuclear proteins.22 As nuclear proteins are the main factors that
drive the transcription of genes, these subtle differences can also
affect the compartmental ratios of one allelic transcript to another.
This type of molecular disturbance has previously been shown to
occur across the human brain and in relation to ZNF804A.23 As a
putative transcription factor, ZNF804A has a large number of
potential targets in both the adult brain and that of the
developing fetus. Hence, the pathogenic consequences of
ZNF804A expression may take hold in early neurodevelopment
and would probably require the coordinated response of multiple
different target genes. The net response of these ZNF804A targets
may therefore explain the strong effect of genotype on the
observed outcome (38 additional hospitalisation days for each A
allele increment). In support of this, manipulation of ZNF804A
expression in gene ‘knock down’ experiments suggest that
regulatory variation within the gene could potentially have effects
on broader transcriptional networks. Hill et al.24 demonstrated,
using a whole-genome approach, that ZNF804A silencing can
affect over 150 different genes that pertain to neuronal migration,
neurite outgrowth and synapse formation.
Considering symptom severity and the nature of the underlying
psychotic disorder as a potential reason for associations with in-
patient outcomes, these effects of rs1344706 variation on gene
expression may explain previously observed psychosis-related
structural changes associated with the risk genotype, such as
Table 2. Risk of admission and total duration of in-patient admission by the rs1344706 genotype
Variable AA (N= 178) AC (N=93) CC (N=20) Total (N= 291)
Any admissions, % (n) 83.7% (149) 83.9% (78) 90.0% (18) 84.2%








Table 3. Association between number of rs1344706 A alleles and total duration of in-patient admission
Adjustments Linear regression output: beta coefﬁcient (95% CI); P-value
Total sample (N= 291) Sample with at least one admission (N= 245)
Unadjusted 28.12 (11.15, 45.07); P = 0.001 34.61 (16.14, 53.08); Po0.001
Adj age 27.19 (10.34, 44.04); P = 0.002 33.62 (15.08, 52.16); Po0.001
Adj gender 25.67 (09.34, 41.99); P = 0.002 31.41 (13.68, 49.15); P= 0.001
Adj genetic ancestry 29.07 (05.92, 52.22); P = 0.014 42.0 (16.13, 67.86); P= 0.001
Adj relationship status 26.03 (09.13, 42.94); P = 0.003 31.24 (12.67, 49.81); P= 0.001
Adj schizophreniform diagnosis 26.78 (08.93, 44.63); P = 0.003a 32.88 (13.15, 52.60); P= 0.001b
Fully adjusted 25.57 (02.55, 48.58); P = 0.029 37.95 (10.47, 65.44); P= 0.007
Abbreviations: Adj, adjusted; CI, conﬁdence interval. Linear regression analysis with bootstrapping. aN= 272 because of missing diagnosis values. bN= 231
because of missing diagnosis values.




Total χ2 (df) P-value
AA AC CC
Agitated behaviour 48.0 33.6 63.2 44.0 0.4 (1) 0.52
Cognitive problems 40.0 28.8 31.6 35.6 2.8 (1) 0.09
Psychotic features 74.7 64.4 89.5 72.05 0.8 (1) 0.78
Depressed mood 51.1 54.8 68.4 53.5 1.74 (1) 0.19
Problems with activities
of daily living
47.7 46.0 42.1 46.5 0.32 (1) 0.57
Abbreviations: df, degree of freedom; HoNOS, Health of the Nation
Outcome Scales.
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impaired connectivity between the prefrontal cortex and the
hippocampus,25 as well as other cognitive26 and symptomatic27
effects. A combination of these and other dysfunctional processes
attributed to rs1344706 might, therefore, explain our observation
of prolonged hospitalisations in the high genetic risk subgroup.
An exploratory analysis comparing HoNOS subscales did not
indicate substantial differences between genotypes, although it is
perhaps noteworthy that those with the AA genotype were more
likely than those with the CC genotype to have cognitive
problems or impaired activities of daily living, and were less likely
to have agitation or hallucinations/delusions. This might indicate a
higher propensity to negative rather than positive symptoms,
although these differences were not signiﬁcant and did not
account for the observed association with the duration of in-
patient stay; furthermore, they are not consistent with previous
research that found higher levels of positive symptomatology in A
allele carriers, but no difference in negative or disorganisation
symptoms.27 However, it is important to bear in mind that these
HoNOS-derived data were not speciﬁcally recorded in relation to
index admissions and may therefore not adequately reﬂect causal
pathways between gene expression and in-patient outcome.
Although use of in-patient services is an important marker of
overall disease severity in psychosis, it is important to bear in mind
that it is inﬂuenced by a number of other factors that could
conceivably account for the association of interest if they also vary
between the genotypes of interest. Differences in response to
pharmacotherapy might also account for the observations.
Previous research, for example, has suggested that rs1344706
may have a role in the genetics of antipsychotic response, namely
two studies of Chinese and Caucasian ﬁrst-episode psychosis
patients, which found that remission of positive symptoms after
4 weeks of supervised antipsychotic medication was signiﬁcantly
reduced in people with the ZNF804a risk allele.28,29 Unfortunately,
however, we did not have speciﬁc data on treatment response in
order to test this hypothesis, which requires further evaluation.
Considering other explanations, we investigated age, gender,
relationship status, ancestry and diagnosis as potential covariates
for this clinical outcome, which did not account for the
associations of interest. Speciﬁcally, although ancestry scores
showed substantial variation between genotypes, adjustment for
ancestry, if anything, strengthened rather than attenuated the
associations between genotype and in-patient outcomes. Causal
pathway factors primarily determined by ancestry are therefore
unlikely explanations. It was beyond the scope of the study to
investigate other potentially relevant factors such as social
support,30 substance use,31 employment32 or accommodation
status,33 which have also been found to inﬂuence duration of in-
patient admission. Data on the duration of untreated psychosis
were also insufﬁcient for analysis. Although service-level factors
are important predictors of length of stay, these are unlikely to be
important for genetic assays in a sample drawn from a single
health-care provider. The fact that the rs1344706 A allele was
associated with longer cumulative duration of in-patient care, but
not with the presence or not of an in-patient admission, suggests
that it might modify psychotic disorder presentation during the
acute phase, or its response to treatment, rather than affecting the
likelihood of a relapse or symptom levels during remission.
Number of in-patient episodes also did not vary by genotype,
consistent with this. However, although some studies have used
admission count as an outcome measure for psychosis, this is
often poorly correlated with other prognostic indicators,34 and
might not have been a sensitive enough outcome during the 2-
year observation period.
Psychiatric genetic studies often look at narrow and well-
deﬁned outcome measures, such as neuropsychological test
scores, that have distant clinical application. A major contribution
of this study was that the outcomes were directly drawn from
clinical data within a relatively large and representative sample of
ethnically and socially diverse people receiving routine clinical
care for their ﬁrst psychotic episode. Moreover, use of in-patient
services as an outcome has a high face validity and a direct utility
in service planning,35 with important implications for an
individual’s recovery potential,36 despite the limitations noted
above. The sample size was relatively high for a ﬁrst-episode
psychosis case series and was adequate to demonstrate the
outcome of interest. Numbers of outcomes chosen for investiga-
tion were relatively small, and only a single genotype of interest
had been examined at the time of analysis, reducing the likelihood
of type 1 statistical error arising through multiple testing.
Limitations, as discussed, principally concern the availability of
data to investigate causal pathways between the genotype and
outcome. Generalisability beyond the ﬁrst-episode period cannot
be assumed and would need further empirical investigation.
Although we could not exclude a small proportion of the patients
having had in-patient admissions outside the geographic catch-
ment during the follow-up period, this is unlikely to have
inﬂuenced the ﬁndings of interest. Assuming our ﬁnding is
replicated, further research is required into mechanisms under-
lying the association we found. Key targets for further evaluation
would include symptom proﬁles and severity experienced during
a relapse, delays in presentation and/or intervention, treatment
resistance and premorbid adjustment and social relatedness. It is
likely that ZNF804A rs1344706 is not alone as a gene-modifying
clinical outcome, but that it acts in combination with other genetic
and environmental factors. Identifying these combinations may
substantially improve the potential to predict prognosis in
psychotic disorders.
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